Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710240 · ClinicalTrials.gov registry record · Phase 1
Indocyanine Green for Central Nervous System Tumors
A Phase 1 study of Suspected Central Nervous System Tumors, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 336
- Enrollment target
- 1
- Study location
NCT02710240: Completed Phase 1 study of Suspected Central Nervous System Tumors, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02710240 is a Phase 1 study of Suspected Central Nervous System Tumors that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 336 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (460% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02710240, a Phase 1 study of Suspected Central Nervous System Tumors, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 336 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a single center, open-label, two-part study to assess image guided surgery of intramolecular imaging in nervous system tumors. Subjects with a diagnosis of a resectable nervous system tumor who are at risk of recurrence are included. The primary goal is to observe what tissues fluoresce in the OR, and then to identify if that tissue is cancerous/tumor or normal when the histopathology is performed.
Primary Outcome
sensitivity of delayed, high dose indocyanine green (second window ICG), as measured by the signal-to-background ratio (SBR)
Conditions Studied
Interventions
- DRUG Indocyanine Green (ICG)
- RADIATION Intraoperative near-infrared (NIR)
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2015-06-10 |
| Est. Completion | 2020-04-02 |
| Phase | Phase 1 |
What the finished NCT02710240 record still lists
NCT02710240 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (460% higher).
The record links to 1 condition, with Suspected Central Nervous System Tumors appearing as the primary indexed condition, and to 2 interventions - of which Indocyanine Green (ICG) is the first listed.
NCT02710240 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02710240 about?
NCT02710240 is a clinical study titled "Indocyanine Green for Central Nervous System Tumors". This study is a single center, open-label, two-part study to assess image guided surgery of intramolecular imaging in nervous system tumors. Subjects with a diagnosis of a resectable nervous system tumor who are at risk of recurrence are included. The primary goal is to observe what tissues fluoresc...
What is the current status of trial NCT02710240?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 336 participants. The study started on 2015-06-10. Estimated completion is 2020-04-02.
What conditions does trial NCT02710240 study?
This clinical trial studies the following conditions: Suspected Central Nervous System Tumors.
What interventions are being tested in trial NCT02710240?
The interventions under investigation include: Indocyanine Green (ICG) (DRUG), Intraoperative near-infrared (NIR) (RADIATION).
Who is sponsoring clinical trial NCT02710240?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710240 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02710240's enrollment target sits among peer trials
336 106th of 2000 higher than 1,893 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI